BeOne Medicines CEO Sells 3,174 ADS for $0.83M – Routine Insider Trade

BeOne Medicines (ONC) filed a routine Form 4 showing CEO/Director John Oyler’s mandatory tax-withholding sale of 3,174 American Depositary Shares (≈41,262 ordinary shares) on 06/23/2025 at an average price of about $262, totaling roughly $0.83 million.

Accepted by SEC EDGAR 06/25/2025 - 05:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 showing CEO/Director John Oyler’s mandatory tax-withholding sale of 3,174 American Depositary Shares (≈41,262 ordinary shares) on 06/23/2025 at an average price of about $262, totaling roughly $0.83 million.

Post-sale, Oyler still controls ≈54.2 million ordinary shares through direct and indirect holdings, so his ownership percentage is effectively unchanged. No other transactions or material changes were disclosed.

Insider Trade Summary

Net Seller: 3,174 shares

Net Sell 2 txns

Insider OYLER JOHN

Role Chief Executive Officer

Sold 3,174 shs ($830K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	3,074	$261.5712	$804K
Sale	American Depositary Shares	100	$262.90	$26K
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 0 shares (Direct); Ordinary Shares — 8,173,759 shares (Direct); Ordinary Shares — 46,055,316 shares (Indirect, See Footnote)

Footnotes (7)

1. F1. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
2. F2. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
3. F3. These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
4. F4. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
5. F5. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.
6. F6. Each American Depositary Share represents 13 Ordinary Shares
7. F7. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BeOne Medicines (ONC) ADS did CEO John Oyler sell on June 23 2025?

He sold 3,174 ADS, each representing 13 ordinary shares.

What was the average price received for the ADS sold by Oyler?

The ADS were sold at prices of $261.5712 and $262.90, averaging about $262 per ADS.

What is the total dollar value of Oyler’s sale reported in the Form 4?

The transaction generated approximately $0.83 million in gross proceeds.

How many ordinary shares does Oyler still own after the reported transaction?

He retains direct and indirect beneficial ownership of ≈54.2 million ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OYLER JOHN

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								8,173,759	D
Ordinary Shares								481,533	I	See Footnote(1)
Ordinary Shares								7,722,480	I	See Footnote(2)
Ordinary Shares								28,204,115	I	See Footnote(3)
Ordinary Shares								9,545,000	I	See Footnote(4)
Ordinary Shares								102,188	I	See Footnote(5)
American Depositary Shares(6)	06/23/2025		S(7)		3,074	D	$261.5712	100	D
American Depositary Shares(6)	06/23/2025		S(7)		100	D	$262.9	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.

2. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

3. These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

4. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

5. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

6. Each American Depositary Share represents 13 Ordinary Shares

7. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.